Accro Bioscience and Fosun Pharma Announce Exclusive License Agreement for AC-201 in Greater China September 3, 2025
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer September 3, 2025
Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
VantAI and Halda Therapeutics Forge Alliance to Discover Next-Generation RIPTAC Medicines August 26, 2025
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib August 26, 2025
N-Power Medicine Launches External Control Arm Platform to Accelerate Oncology Drug Development and Reduce Reliance on Randomization August 26, 2025
Discovery research reduced to support registrational trials for ORIC-944 and ORIC-114 August 19, 2025
CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers August 19, 2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes August 12, 2025
Strand Therapeutics Raises $153M Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline August 12, 2025
NeOnc Technologies Awarded $2.5M in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia in Ph 2 trials August 12, 2025
